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Abstract
Background
Inappropriate use of multiple medicines (inappropriate polypharmacy) is a major challenge
in older people with consequences of increased prevalence and severity of adverse drug
reactions and interactions, and reduced medicines adherence. The aim of this study was to
determine the levels of consensus amongst key stakeholders in the European Union (EU) in
relation to aspects of the management of polypharmacy in older people.
Methods
Forty-six statements were developed on aspects of healthcare structures, processes and
desired outcomes, with consensus defined at 80% agreement. Panel members were
strategists (e.g. directors, leading clinicians and commissioners) from each of the 28 EU
member states, with a target recruitment of five per member state. Three Delphi rounds
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were conducted via email, with panel members being provided with summative results and
collated, anonymised comments at the commencement of Rounds 2 and 3.
Results
Ninety panel members were recruited (64.3% of target), with high participation levels
throughout the three Delphi rounds (91.1%, 83.3%, 72.2%). During Round 1, consensus
was obtained for 27/46 statements (58.7%), with an additional two statements in Round 2
and none in Round 3. Consensus was obtained for statements relating to: potential gain
arising from polypharmacy management (3/4 statements); strategic development (7/7);
change management (5/7) indicator measures (4/6); legislation (0/3); awareness raising
(5/5); polypharmacy reviews (5/7); and EU vision (0/7). Analysis of free text comments indi-
cated that the vision statements were too ambitious and not achievable by the specified
timeframe of 2025.
Conclusion
Consensus was obtained amongst key EU strategists around many aspects of polyphar-
macy management in older people. Notably, no consensus was achieved in relation to state-
ments relating to the need to alter legislation in areas of healthcare delivery, remuneration
and practitioner scope of practice. While the vision for the EU by 2025 was considered rather
ambitious, there is great potential and clear opportunity to advance polypharmacy manage-
ment throughout the EU and beyond.
Introduction
Recent years have seen marked shifts in global population demographics, with increasing life
expectancy, numbers, and proportions of older people [1]. Healthy and active ageing, ‘the pro-
cess of optimising opportunities for health, participation and security to enhance quality of life
as people age’ [2], through the design and delivery of person-centred healthcare, is fundamen-
tal to the health policies of many countries [3,4]. This is not without its challenges given the
association between age and prevalence of multimorbidity [5,6], in addition to the consequent
increases in healthcare services utilisation [7], and reduced quality of life [8]. Furthermore,
there is extensive global evidence of the high frequency of prescribing potentially inappropriate
medicines in older, multimorbid people [9–11]. Appropriate prescribing of medicines in older
people is challenging given age-related physiological changes which impact pharmacodynam-
ics and pharmacokinetics While the plethora of evidence based guidelines for single disease
states may provide support, they do not provide sufficient coverage of issues relating to multi-
morbidity [12].. The cumulative impact of treatment recommendations results in the prescrib-
ing of an overwhelming number of medicines [13].
Polypharmacy is a widely used term which traditionally was interpreted as the concomitant
use of four or five different prescribed medicines [14,15]. This emphasis on the number of
medicines has come under criticism for being arbitrary and not considering appropriateness
in the individual More recently, it has been suggested to adopt the terms ‘inappropriate poly-
pharmacy’ (prescribing of multiple medicines which are either inappropriate or no longer
indicated) and ‘appropriate’ or ‘optimal polypharmacy’ (appropriate prescribing of multiple
medicines) [16]. Inappropriate polypharmacy has been described as ‘one of the greatest
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prescribing challenges’ [13], with consequences including increased prevalence and severity of
adverse drug events and drug interactions, and reduced medicines adherence [13–16].
Although the goals of managing inappropriate polypharmacy and striving for appropriate
polypharmacy are paramount, there is a lack of high level evidence on optimal approaches. A
systematic review of the effectiveness of interventions to improve appropriate polypharmacy
and reduce medicines-related problems in older people highlighted the uncertainty of which
specific elements of interventions impacted appropriate polypharmacy [16]. A more recent
systematic review and meta-analysis explored the impact of strategies to reduce inappropriate
polypharmacy on outcomes of mortality, hospitalisation and change in number of medicines
prescribed. The authors noted that the interventions were complex and concluded that there is
no convincing evidence that the strategies were effective in reducing inappropriate polyphar-
macy or had an impact on clinically relevant endpoints [17]. This is despite the numerous dif-
ferent tools developed to promote appropriate prescribing in older people, many of which lack
methodological robustness and validation in clinical settings [18]. While there is a need for evi-
dence based guidance on the management of inappropriate polypharmacy and promoting
appropriate polypharmacy in older people, focus on the implementation and sustainability of
systems and processes is also warranted.
SIMPATHY (Stimulating Innovation Management of Polypharmacy and Adherence in
The Elderly) was a pan-European initiative, funded by the European Commission to help
address the issue of inappropriate polypharmacy across the European Union (EU). SIMPA-
THY aims to stimulate, promote and support innovation across the EU in the management of
appropriate polypharmacy in the elderly, in order to contribute to efficient and sustainable
healthcare systems [14]. There is emphasis on translating evidence to practice impacting
healthcare structures, processes and patient outcomes (clinical, humanistic and economic).
Work packages comprise a systematic review of the published and grey literature of identified
policies and guidelines; case studies of the management of polypharmacy; a benchmarking
survey; and PESTEL (Political, Economic, Sociocultural, Technological, Environmental and
Legal) and SWOT (Strengths, Weaknesses, Opportunities and Threats) analyses. Results have
demonstrated clearly the diversity across the EU and that there is opportunity to harness
expertise and experiences.
The aim of this study was to determine the levels of consensus amongst key stakeholders in
the EU in relation to aspects of the management of polypharmacy in older people. Particular
consideration was given to aspects of structures, processes and desired outcomes around the
promotion of appropriate polypharmacy.
Methods
Design
A consensus-based approach, utilising a modified Delphi technique, was employed. Consen-
sus, also referred to as ‘collective agreement’, designs are employed in a variety of circum-
stances, notably to develop guidelines and policies in situations of limited evidence [19].
Consensus designs are group facilitation approaches which aim to determine the level of con-
sensus among a group of experts (stakeholders) by aggregation of opinions into refined agreed
opinion. The three main consensus designs are the Delphi technique, the consensus develop-
ment technique and the nominal group technique [20–22]. The Delphi technique typically
requires multiple administrations of anonymised questionnaires, usually over two or three
rounds [23]. The first round of data collection, in the classic Delphi technique, generates
qualitative data which is then used to guide development of statements for the questionnaires
rounds. A modified Delphi technique, which omits the qualitative round, can be employed in
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those situations where the statements are derived from the literature or previous research, as
in this study. Both classic and modified Delphi techniques afford participants anonymity,
thereby ensuring that dominant participants do not unduly influence data collection. The Del-
phi technique is further characterised by participant feedback of statistical data and comments,
affording participants the opportunity to reconsider their initial responses in subsequent
rounds [24,25]. Given the need to collect data across the EU, the modified Delphi technique
was selected over the consensus development technique and the nominal group technique
which require participants to meet face to face.
Statement development
The statements for the first round of the Delphi were developed from the findings generated
from previous work undertaken as part of the SIMPATHY project, including focus groups and
discourse analysis of face to face interviews [14]. Statements focused on structures, processes
and desired outcomes around the promotion of appropriate polypharmacy in older people.
Draft statements were developed and reviewed by members of the project team for appropri-
ateness and clarity.
The Round 1 questionnaire was developed in Survey Monkey (Survey Monkey Inc., San
Mateo, California, USA) and functionality pilot tested by the project team.
Determining consensus
A six-point Likert scale was used for participants to rate their level of agreement or disagree-
ment with each statement: strongly disagree; disagree; somewhat disagree; somewhat agree;
agree; and strongly agree. A variety of means of assessing the point of consensus have been
outlined in the literature: a predetermined number of rounds; subjective analysis; certain level
of agreement; average percent of majority opinions cut-off rate; mode, mean, median ratings
and rankings; interquartile range; coefficient of variation; and post-group consensus [26].
While there is no agreement on the best approach, the ‘certain level of agreement’ is the most
commonly used and hence was adopted. In addition, there is no accepted, set standard for the
target percentage of agreement, and while 70% (summative of agree and strongly agree) is
commonly reported in the literature, given the importance of promoting appropriate poly-
pharmacy, the consensus was deemed to have been met at 80% (summative of agree and
strongly agree) for each individual statement.
Expert panel members
Appropriate selection of ‘expert panel members’, or participants, is critical in promoting
robustness and data validity. For this Delphi, the panel were to be five members from each EU
member state (n = 28), giving a total of 140 members. Furthermore, these five would represent
one policy maker, two healthcare commissioners, one healthcare provider director level and
one clinician (physician or pharmacist).
Recruitment of expert panel members
The recruitment and engagement of the panel members is crucial to the success of any Del-
phi. Response rates are typically 85% and any reduction may compromise the internal and
external validity of the findings [26]. For SIMPATHY partner countries (United Kingdom
[Scotland, Northern Ireland], Italy, Germany, Greece, Poland, Portugal, Spain), one member
of the project team in that country was responsible for the initial contact with potential par-
ticipants and for securing agreement to participate. Project team members employed several
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approaches including their professional networks, those of colleagues etc. In addition, those
initial contacts unable to participate were requested to nominate other like individuals. This
was continued until the required number and types of panel members were recruited or
until the end of the time period for recruitment. For non-partner countries, several sources
including professional networks were used to identify potential panel members. These were
allocated to members of the project team and a similar approach to recruiting within partner
countries was adopted. Each potential panel member was provided with full study informa-
tion, outlining the aim of the Delphi, the extent and timing of their expected involvement
and the potential societal benefits. In addition, they were each requested to complete, and
return electronically, a consent form.
Delphi rounds
Round 1. At the point of commencing the Delphi in November 2016, each panel member
was sent an email with a link to the online questionnaire. In addition to the Delphi statements,
the online questionnaire captured the professional role and country of residence of each panel
member. A two-week deadline was set for rating levels of agreement or disagreement with
each statement. A comments box was included for each statement, allowing justification of
responses and the opportunity to propose new statements. All panel members were sent a
reminder email at weekly intervals. Data generated from completing the online questionnaire
were extracted to Microsoft Excel for descriptive analysis (frequencies and percentages) to
identify whether or not consensus had been obtained for each statement. A content analysis
approach was performed on any textual responses [27].
Round 2. In Round 2, collective feedback of all panel members’ Round 1 responses was
provided, highlighting levels of consensus achieved for each statement and also all comments
for each statement where consensus was not achieved. The Round 2 questionnaire required
participants to rate only those statements that did not meet consensus in round one. As in
Round 1, a two-week deadline was given for completion and return, with the approach to
reminders and analysis the same as Round 1.
Round 3. Round 3 proceeded as per Round 2. Those statements not achieving consensus
in Round 3 were deemed non-agreement.
Results
Expert panel member recruitment
Ninety-five expert panel members were recruited, with four EU member states over-recruiting,
giving an adjusted recruitment rate of 90/140, 64.3%. The target of five experts per member
state was achieved in 13/28 states, 46.4%, with no recruitment in six (21.4%) member states
(Croatia, Estonia, France, Latvia, Lithuania, Luxembourg).
Expert panel member participation
The participation of panel members is given in Table 1, with rates of 91.1%, 83.3% and 72.2%
achieved in Rounds 1, 2 and 3 respectively. The target of five members per EU member state
was achieved in eight states in Round 1, five in Round 2 and three in Round 3.
Panel member roles are given in Table 2, with many having multiple roles. The recruitment
of commissioners was particularly challenging.
An EU Delphi study on structures, processes and desired outcomes of polypharmacy management
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Statement consensus
Consensus was obtained for 27/46 (58.7%) statements in Round 1, with consensus obtained
for a further two statements (29/46, 63.0%) in Round 2 and nil in Round 3. Tables 3–8 illus-
trate those statements for which consensus was obtained, presented according to each of the
Table 1. Panel member participation in each of the three Delphi rounds.
Country Round 1 Round 2 Round 3
Austria 4 4 4
Belgium 3 3 3
Bulgaria 1 0 0
Croatia 0 0 0
Cyprus 3 3 3
Czech Republic 3 3 3
Denmark 5 4 3
Estonia 0 0 0
Finland 3 4 4
France 0 0 0
Germany 5 5 5
Greece 5 5 4
Hungary 5 5 3
Ireland 4 4 3
Italy 2 1 1
Latvia 0 0 0
Lithuania 0 0 0
Luxembourg 0 0 0
Malta 2 2 2
Netherlands 5 3 2
Poland 5 4 4
Portugal 4 5 2
Romania 3 1 2
Slovakia 2 1 1
Slovenia 5 5 5
Spain 4 4 3
Sweden 4 4 3
United Kingdom 5 5 5
Total participation 82/90 (91.1%) 75/90 (83.3%) 65/90 (72.2%)
https://doi.org/10.1371/journal.pone.0188348.t001
Table 2. Professional roles of Delphi panel members.
Roles Round 1
(n = 82)
Round 2
(n = 75)
Round 3
(n = 65)
Lead/ Director/ Head/ Chief/ Chair 30 27 19
Physician 29 29 21
Pharmacist 28 28 23
Academic 22 19 18
Commissioner 5 2 4
Politician 1 1 0
Nurse 1 0 0
Patient organisation 1 1 0
https://doi.org/10.1371/journal.pone.0188348.t002
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distinct sections. Consensus was obtained as follows for statements relating to: potential gain
arising from polypharmacy management (3/4 statements); strategic development (7/7); strate-
gic change management (5/7); indicator measures (4/6); legislation (0/3); awareness raising
(5/5); polypharmacy reviews (5/7); and EU vision (0/7).
Table 3. Number of responses and % agreement (strongly agree/agree) to statements relating to potential gain arising from polypharmacy
management.
Statements SD D So D So A A SA % A
There is a need for an EU level coordinated approach to identify, share, disseminate, promote and support best
practice around polypharmacy management (n = 82, Round 1)
0 2 1 3 36 40 93
Polypharmacy management should lead to considerable health gain (n = 82, Round 1) 0 1 0 7 33 41 90
Polypharmacy management should lead to better healthcare workforce utilisation and efficiency (n = 82, Round 1) 0 0 3 8 44 27 87
(SD = strongly disagree, D = disagree, So D = somewhat disagree, So A = somewhat agree, A = agree, SA = strongly agree, %A = % agreement)
https://doi.org/10.1371/journal.pone.0188348.t003
Table 4. Number of responses and % agreement (strongly agree/agree) to statements relating to strategic development.
Statements SD D So D So A A SA % A
Leaders of polypharmacy management should articulate a clear vision encompassing aims, objectives, motivating
factors and outcomes (n = 82, Round 1)
0 0 0 3 37 42 96
Leaders of polypharmacy management should ensure that the strategic vision is shared and understood by all
involved in implementation (n = 82, Round 1)
0 0 0 4 28 50 95
Polypharmacy management should be overseen by a diverse range of stakeholders including policy makers,
physicians, pharmacists, nurses, and patients or patient advocates (n = 82, Round 1)
1 0 3 6 28 44 88
Polypharmacy management should be incorporated into health policy strategies at local, regional and national levels
that guide the course of care delivery (n = 82, Round 1)
0 0 0 5 34 43 94
Polypharmacy management should be evaluated fully prior to large scale implementation, encompassing both
quantitative outcome measures and the perspectives of key stakeholder groups (n = 81, Round 1)
1 2 5 9 35 39 79*
Information and communications technology tools should be developed and implemented across all healthcare
settings to support polypharmacy management (n = 81, Round 1)
0 0 1 3 31 46 95
Polypharmacy management should be developed as essential components of larger initiatives in the healthcare
system such as patient safety, management of long term conditions, and care for older people (n = 82, Round 1)
0 1 0 3 28 50 95
(SD = strongly disagree, D = disagree, So D = somewhat disagree, So A = somewhat agree, A = agree, SA = strongly agree, %A = % agreement)
* statements with 79% agreement were so close to the 80% cut-off that they were also deemed as achieving consensus
https://doi.org/10.1371/journal.pone.0188348.t004
Table 5. Number of responses and % agreement (strongly agree/agree) to statements relating to change management.
Statements SD D So D So A A SA % A
When developing polypharmacy management, leaders should develop an explicit change management strategy and
plan (n = 82, Round 1)
0 0 5 12 39 26 79*
Prior to implementation of polypharmacy management, the culture of the organisation should be assessed for both
strengths and potential barriers to implementation (n = 82, Round 1)
0 3 2 6 33 28 87
A detailed assessment of the need for additional resources required to support the implementation and evaluation of
polypharmacy management should be undertaken (n = 82, Round 1)
0 4 2 11 36 29 79*
Leaders of polypharmacy management should work across care settings and boundaries to ensure implementation is
in a standard manner throughout the health system (n = 82, Round 1)
1 1 2 13 28 37 79*
The development of the clinical pharmacy workforce, particularly in primary care, will be a key enabler of service
provision around polypharmacy management (n = 75, Round 2)
1 0 4 7 26 37 84
(SD = strongly disagree, D = disagree, So D = somewhat disagree, So A = somewhat agree, A = agree, SA = strongly agree, %A = % agreement)
* statements with 79% agreement were so close to the 80% cut-off that they were also deemed as achieving consensus
https://doi.org/10.1371/journal.pone.0188348.t005
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Statement non-consensus
Following three rounds, consensus was not obtained for 17 statements. Levels of agreement
for each statement are provided in Table 9.
Many panel members provided detailed comments to explain their responses. Content
analysis of these in relation to statements where consensus was not achieved identified several
key, recurring themes.
Table 6. Number of responses and % agreement (strongly agree/agree) to statements relating to indicator measures.
Statements SD D So D So A A SA % A
There is a need to develop valid, reliable and sensitive indicators to quantify the extent of inappropriate and
appropriate polypharmacy (n = 82, Round 1)
1 1 3 4 29 44 89
There is a need to develop valid, reliable and sensitive indicators to quantify the impact on patient clinical outcomes
relating to the extent of inappropriate and appropriate polypharmacy (n = 82, Round 1)
0 1 1 7 21 52 89
Valid, reliable and sensitive process indicators relating to polypharmacy management should be developed (n = 82,
Round 1)
0 1 1 10 32 38 85
Data relating to valid, reliable and sensitive indicators of inappropriate and appropriate polypharmacy should be
reported routinely to key stakeholder groups at local, regional and national levels (n = 75, Round 2)
0 0 3 7 30 34 85
(SD = strongly disagree, D = disagree, So D = somewhat disagree, So A = somewhat agree, A = agree, SA = strongly agree, %A = % agreement)
https://doi.org/10.1371/journal.pone.0188348.t006
Table 7. Number of responses and % agreement (strongly agree/agree) to statements relating to awareness raising.
Statements SD D So D So A A SA % A
There is a need to increase awareness of the issues relating to polypharmacy amongst health policy leaders (n = 82,
Round 1)
0 0 2 5 27 48 92
There is a need to increase awareness of the issues relating to polypharmacy amongst health professional leaders
(n = 82, Round 1)
0 0 3 9 24 46 85
There is a need to increase awareness of the issues relating to polypharmacy amongst patient representative leaders
(n = 82, Round 1)
0 0 0 11 24 47 87
Education on polypharmacy management needs to be integrated into undergraduate curricula for all health
professionals, particularly doctors, pharmacists and nurses (n = 82, Round 1)
0 1 0 7 11 63 90
Polypharmacy management needs to be integrated into continuing professional development programmes for all
health professionals, particularly doctors, pharmacists and nurses (n = 82, Round 1)
0 0 0 5 21 56 94
(SD = strongly disagree, D = disagree, So D = somewhat disagree, So A = somewhat agree, A = agree, SA = strongly agree, %A = % agreement)
https://doi.org/10.1371/journal.pone.0188348.t007
Table 8. Number of responses and % agreement (strongly agree/agree) to statements relating to patient centred polypharmacy reviews.
Statements SD D So D So A A SA % A
There is a need for evidence based guidelines promoting a systematic approach to patient centred polypharmacy
reviews (n = 82, Round 1)
0 0 1 12 23 46 84
The roles and responsibilities of the members of the multidisciplinary team delivering patient centred polypharmacy
reviews must be clearly defined and articulated (n = 82, Round 1)
0 0 1 9 33 39 88
Clinical decision support systems should be developed and implemented to facilitate patient centred polypharmacy
reviews (n = 82, Round 1)
0 0 0 9 31 42 89
Those involved in delivery of patient centred polypharmacy reviews should have electronic access to all relevant
patient information (n = 82, Round 1)
0 0 0 6 24 52 93
All affected patients, regardless of setting or environment, should have access to a polypharmacy review (n = 82,
Round 1)
0 1 4 10 24 43 82
(SD = strongly disagree, D = disagree, So D = somewhat disagree, So A = somewhat agree, A = agree, SA = strongly agree, %A = % agreement)
https://doi.org/10.1371/journal.pone.0188348.t008
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Many commented on the lack of evidence that polypharmacy management should lead to
considerable economic societal gain,
‘It might even be more expensive, e.g. interventions are expensive and up to now it has not
been shown that polypharmacy management is effective.’
One commented that economic gain was not a key priority,
Table 9. Statements for which consensus was not obtained.
Statements relating to. . . % Agreement
Round
1,
n = 82
Round
2,
n = 75
Round
3,
n = 65
. . . potential gain arising from
polypharmacy management
Polypharmacy management should lead to considerable economic societal gain 72 65 66
. . . strategic change management Health systems should design payment mechanisms and incentives that align with
the work required to implement polypharmacy management
71 67 69
To facilitate implementation, polypharmacy management should be captured within
contractual arrangements for health professionals
59 43 40
. . .indicator measures There is a need to develop valid, reliable and sensitive indicators to quantify the
economic impact relating to the extent of inappropriate and appropriate
polypharmacy
72 73 72
Valid, reliable and sensitive indicators of inappropriate and appropriate
polypharmacy should be developed at the EU level
59 48 43
. . .legislation Legislation governing healthcare delivery that limits the implementation of
polypharmacy management should be addressed as part of a long-term
implementation plan
63 55 66
Legislation governing remuneration for healthcare services that limits the
implementation of polypharmacy management should be addressed as part of a
long-term implementation plan
60 63 60
Legislation governing the scope of practice of relevant health professionals (e.g.
nurses, pharmacists) that limits the implementation of polypharmacy management
should be addressed as part of a long-term implementation plan
67 62 68
. . .patient centred polypharmacy
reviews
There is a need for common EU evidence based guidelines promoting a systematic
approach to patient centred polypharmacy reviews
66 71 69
Each EU member state should develop their own national or regional evidence
based guidelines promoting a systematic approach to patient centred polypharmacy
reviews
45 43 65
. . .the vision for the EU by 2025 By 2025, European healthcare will be recognised widely for effective policies on the
management of polypharmacy through multidisciplinary teams
57 55 52
By 2025, innovative, coordinated and comprehensive interventions will be in place
across Europe, in all settings, supporting patient empowerment, safety and
addressing polypharmacy management
56 37 37
By 2025, integrated, user friendly dedicated information and communications
technology tools will be supporting the management of polypharmacy
65 64 65
By 2025, information and communications technology systems in all healthcare
organisations will be facilitating improved communication between all healthcare
providers
63 67 65
By 2025, each citizen will have a personalised healthcare record incorporating full
medicines information
57 63 65
By 2025, patient involvement and empowerment will be a key priority in all
healthcare related developments
74 75 77
By 2025, there will be a 50% reduction (compared to the current level) in patients
receiving inappropriate polypharmacy
45 32 25
https://doi.org/10.1371/journal.pone.0188348.t009
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‘Economic outcomes are not the main goal. Our priority and main goals are the patient safety
and efficacy, and efficiency.’
The theme of high quality care also emerged in relation to statements on payment mecha-
nisms and incentives, contractual arrangements and legislation,
‘I think, that implementing polypharmacy management should be somehow the concern of
health professionals, doctors, nurses, pharmacists and it shouldn't be connected with addi-
tional gratification’,
‘Doctors and pharmacists don't need legislation governing remuneration for their healthcare
services.’
There were mixed opinions around the need for economic related indicators of polyphar-
macy management. While some appeared keen to support indicator development,
‘Quantification of economic impact could generate resources for the deployment of more health
care professionals’,
‘Health services and polypharmacy have a cost, thus, economic evaluation is mandatory with
well-defined indicators’,
others viewed these as less important,
‘For me, on a personal level, this is less important than the clinical outcomes. Yet, without
any sound financial backing or background, national stakeholders will probably not want
to provide financial support. But even then, I think (and I cannot base this on any evidence
whatsoever) that the increased incidence of clinical outcomes is the main driver for increased
costs.’
There were also diverse comments around the need for indicators to be developed at the
EU level. While some considered this to be of benefit in terms of enabling change,
‘Comparison is one of the drivers to change; also it would be interesting to see the outcome of
such consensus’,
others noted the likely difficulty of obtaining agreement,
‘Very difficult to get consensus in this topic. Each country is different. Health care models are
different too.’
A similar theme emerged in terms of common EU evidence based guidelines around poly-
pharmacy management,
‘Yes, this will give the opportunity for all EUmember countries to work together and provide
better guidelines’
‘Not all EU countries have the potential, experience and resources to develop their own
national or regional evidence based guidelines. Sharing information, experience, and effective
collaboration could be cost effective.’
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Others, however, were more sceptical that an EU approach was likely to be effective and pre-
ferred a national approach,
‘More focus on national context based patient centred polypharmacy reviews (e.g. integrated
care, with collaboration of GPs) is better than to put energy in EU based guideline development.’
One suggested combining EU and national approaches,
‘There is no need for doing the same work in each country, it would be better with an EU
guideline, that can be adopted according to the local setting.’
Consensus was not achieved for any of the SIMPATHY vision statements. The overwhelming
theme was that while these were aspirational, they were not considered achievable within the
timescale,
‘A fine ambition, but I don’t think this will happen’
‘We have been working for almost 5 years on this specific subject; there are still too many
unknowns’
‘I am not sure about the exact year, if this is possible in 8 years. . ..!!! In my opinion policy
change needs also a change in legislation and practising and 8 years´ period is really short for
both changes (in the whole EU)’
‘That would be great, but I'm not sure if possible in this period of time. I think more like 2030–
40.’
Discussion
Statement of key findings
During the course of the three Delphi rounds, consensus was achieved for 29 statements
(63.0%). Key areas of consensus were around potential gain arising from polypharmacy man-
agement, strategic development, strategic change management, indicator measures, awareness
raising and patient centred polypharmacy reviews. The main areas of non-consensus were in
relation to legislation and the SIMPATHY vision for polypharmacy management in the EU by
2025. Panel members felt generally that there was no need for changes in legislation to support
aspects of polypharmacy management. For the SIMPATHY vision for the EU by 2025, analysis
of the comments provided by panel members indicated that these statements were considered
too ambitious and not achievable within the timeframe of 2025.
Strengths and weaknesses
Best practice in conducting consensus studies was followed throughout this modified Delphi
study. A high level of engagement was achieved across the EU, and while this decreased as
the rounds progressed, the lowest response rate was 72.2%. Many, and often detailed, com-
ments were received from panel members to justify their responses. The panel members repre-
sented a spectrum of director level physicians, pharmacists, nurses, academics and patient
representatives.
There are, however, some weaknesses to the Delphi study hence the findings should be
interpreted with caution. Despite all efforts, the target to recruit five panel members per EU
member state was only achieved in 11 member states, with no recruitment in six member
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states. Furthermore, in Round 1, the target of five responses per member state was only
achieved in eight member states, with this falling to six in Round 2 and three in Round 3. Very
few commissioners or politicians were recruited, with most panel members being director
level health professionals. Given the key roles of commissioners and politicians in resource
allocation and leading change, the lack of involvement is a weakness which may be due to the
busy work schedules of these individuals. Recruitment and response biases may have been
present, with those recruited and participating being those most positive. These weaknesses
may have resulted in skewed finding, potentially limiting the generalisability of the results to
the entire EU and beyond.
Interpretation of findings
The appropriate use of medicines to achieve optimal health outcomes and quality of life forms
one key element of the global drive to promote active and healthy ageing [2]. Given the preva-
lence of multimorbidities in older people and the extent of inappropriate polypharmacy
[5,6,9–11], there is a need for urgent action to ensure effective and efficient deployment of
healthcare structures and processes within the context of person-centred care. There is an
opportunity for EU member states, organisations and associations to harness the expertise in
this area, to define best practice, learn from each other and agree key targets and associated
action plans. Given the extent of engagement across the EU, the findings of this consensus
study may facilitate such developments within the EU and beyond. Notably, almost all panel
members (93%) agreed that a co-ordinated approach at the EU level was warranted to identify,
share, disseminate, promote and support polypharmacy management. While this will take
considerable effort to operationalise, the World Health Organization has recently launched a
global initiative aiming to reduce the level of severe, avoidable harm related to medications by
50% over the next five years [28]. Within this initiative, polypharmacy is one of the three key
areas where countries and key stakeholders are asked to make strong commitments and to
take action. There is also a need to better generate the evidence and disseminate findings
from any national initiatives. Related SIMPATHY research identified that of the many regional
or national guidance documents on the management of polypharmacy in older people, there
was only one peer reviewed publication which described the development of the guidance and
none which reported impact [14].
Although there were high levels of consensus around potential health gain (90%) and
healthcare utilisation, and efficiency (87%), which could result from optimal polypharmacy
management, the research literature in this field is lacking, as evidenced by the conclusions of
two recent systematic reviews [16,17]. Consensus was not obtained around economic societal
gain, comments highlighted the lack of evidence. A very recent systematic review of economic
gain arising from medication reviews highlighted that most studies were of poor quality, had
been conducted only in hospital settings and that limited parameters were included in the eco-
nomic evaluation [29].
Consensus was achieved for all seven statements based on strategic development in terms
of the need for a clearly articulated vision (96%), which is shared widely and understood at
all levels including patients and their advocates (95%). The goals and aspirations of patient
engagement and involvement in healthcare planning, intervention design, development and
evaluation are key priorities globally [3,4]. There were also high levels of agreement that poly-
pharmacy management should be integrated within healthcare policies at all levels (94%) and
that it should be integrated within initiatives such as the management of long term conditions
(95%). Integrated care is a rapidly developing field, evidenced by the introduction of the Inter-
national Journal of Integrated Care in 2000, followed by the establishment of the International
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Network of Integrated Care (now Foundation) in 2004 [30]. While there are many definitions
of integrated care), a primary focus is addressing fragmented healthcare to enable better coor-
dinated and continuous care that improves patient experience and achieves greater efficiency
and value [31]. There have been calls to include pharmacists in integrated care teams [32], and
a recent meta-analysis showed that integrating pharmacists into these teams improved thera-
peutic, safety, hospitalization, and adherence outcomes [33].
All statements on strategic change management achieved high levels of consensus except
those relating to payments and contractual arrangement for health professionals, with several
commenting that there was no need for such payments or changes to contracts. Similar
responses were received around the need for legislative change to promote polypharmacy
management. Statements on change management were based on findings of the SIMPATHY
case studies in which facilitators and barriers of change were identified using Kotter’s 8-Step
Change Model [34]. One key area of consensus was around assessing organisational culture to
identify enablers and barriers to change (87%). There are many different definitions of organi-
sation culture such as ‘the pattern of basic assumptions that a given group has invented, dis-
covered, or developed in learning to cope with its problems of external adaptation and internal
integration. . .’ [35].. This encapsulates aspects such as values, learning, perceptions, beliefs
and practices at all levels of an organisation. Acknowledging that the objective measurement
of these aspects and hence culture are notoriously complex and fraught with limitations, there
is evidence that within the field of patient safety, interventions can improve safety culture,
potentially reducing patient harm [36]. Focusing more on the culture of the organisation may
enhance the implementation of interventions around polypharmacy management.
Generating high levels of quantitative evidence of impact of change requires the application
of valid, reliable and sensitive outcome measures and indeed there were high levels of consen-
sus around the need to develop these (89%). A systematic review of the outcomes reported in
trials of medication review in older patients noted the need for a standardised core outcome
set to improve outcome reporting and evidence synthesis [37]. A recent consensus study of 19
Delphi panellists aimed to develop such a core outcome set for effectiveness trials aimed at
optimising prescribing in older adults in care homes. Thirteen outcomes (organised into seven
overarching domains: medication appropriateness, adverse drug events, prescribing errors,
falls, quality of life, all-cause mortality and admissions to hospital (and associated costs)) met
the criteria for inclusion in the final set [38]. While these outcomes are orientated towards
care homes, they may also be of use in other settings. The current study points to the need to
develop similar outcomes relating to process indicators of polypharmacy management. No
consensus was obtained around the need for economic indicators or that indicators should be
developed at the EU level, which is surprising given that the processes of polypharmacy man-
agement are likely to be similar.
Consensus was also achieved for most statements relating to the processes of patient centred
medication reviews in the areas of need for evidence based guidelines (84%), defining the roles
and responsibilities of healthcare professionals (88%) and the need for clinical decision support
systems (89%). Interestingly, there was no agreement over the need for common EU evidence
based guidelines or each EU member state developing their own guidelines. There is an appar-
ent dilemma between the efficiency gained in common guidelines and the lack of ownership
and possible contextualisation. It may be that there are common evidence based approaches
to the process of medication reviews. This may include the use of many of the explicit and
implicit measures of prescribing appropriateness [18] and issues such as the allocation of tasks
to specific health professionals which may depend on issues such as competence. For example,
while independent prescribing by pharmacists and nurses is widespread in the United King-
dom [39], this is not within the legislative framework of many EU member states.
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The statements which had the lowest levels of consensus were those around the SIMPA-
THY vision for polypharmacy management in the EU by 2025 and indeed consensus was
not achieved for any of these statements. A vision statement is defined as ‘a declaration of an
organisation’s objectives, ideally based on economic foresight, intended to guide its internal
decision-making’ [40]. Analysis of comments indicated that while these were considered
aspirational, they were not achievable within the proposed timeframe of 2025. It may be that
members of the SIMPATHY project viewed the vision statement as aspirational and as a tool
to create a sense of urgency, whereas the Delphi participants considered it on more practical
terms.
Further work
It is acknowledged that consensus based approaches generate a lower level of evidence than
can be derived from experimental designs such as randomised controlled trials. Robust
research is therefore warranted to progress from the Delphi study to further the development,
implementation and evaluation of polypharmacy management on an international level. The
United Kingdom Medical Research Council Framework relating to complex interventions
could form the basis for such developments in terms of refining and further developing guid-
ance [41]. This is then followed by phases of feasibility and pilot testing prior to wide scale
evaluation incorporating objective indicators of processes and outcomes together with nested
qualitative research exploring processes from multiple perspectives.
Conclusions
In conclusion, consensus was obtained amongst key stakeholders in the EU in relation to
many aspects of the management of polypharmacy in older people. Key areas of consensus
were around potential gain arising from polypharmacy management, strategic development,
strategic change management, indicator measures, awareness raising and patient centred poly-
pharmacy reviews. Notably, no consensus was achieved in relation to statements relating to
the need to alter legislation in areas of healthcare delivery, remuneration and practitioner
scope of practice. While the SIMPATHY vision for the EU by 2025 was considered rather
ambitious, there is great potential and clear opportunity to advance polypharmacy manage-
ment throughout the EU and beyond.
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